Interestingly, the recently developed small molecule inhibitor CUDC-907, targeting both HDAC and PI3K, shows activity in many human cancer cell lines and xenografts and, additionally, the molecule seems to block treatment escape of cancer cells by also blocking the RAF-MEK-MAPK pathway [153]. This evidence concerns the gene HDAC9 and cancer.